Vanguard Asset Management
CAPR icon

Vanguard Asset Management’s Capricor Therapeutics CAPR Stock Holding History

Vanguard Asset Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$777K Hold
32,265
– – ﹤0.01% 2006
2026
Q1 		$981K Buy
+32,265
New +$860K ﹤0.01% 1802

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Asset Management's CAPR Position: Q2 2026 in Review

Vanguard Asset Management held its Capricor Therapeutics (CAPR) position steady in Q2 2026 at 32,265 shares worth $777K. The position accounts for ﹤0.01% of the portfolio, ranked #2006.

Vanguard Asset Management first reported a position in CAPR in Q1 2026 and has held it in 2 quarters since. The position peaked at $981K in Q1 2026. 155 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Vanguard Asset Management held 32,265 shares of Capricor Therapeutics worth $777K as of Q2 2026.
  • Vanguard Asset Management left its Capricor Therapeutics share count unchanged in Q2 2026.
  • Capricor Therapeutics made up ﹤0.01% of Vanguard Asset Management's portfolio in Q2 2026, its #2006 holding.
  • Vanguard Asset Management first reported a position in Capricor Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Asset Management's Capricor Therapeutics position peaked at $981K in Q1 2026.
  • 155 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Vanguard Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.